We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




microRNA Expression Regulates Tumor Growth in Mouse Lung Cancer Model

By LabMedica International staff writers
Posted on 27 Sep 2010
Levels of a specific microRNA, miR-21, have been found to regulate the progression of non-small-cell lung cancer (NSCLC) in a mouse model.

To study the in vivo roll of miR-21 in NSCLC investigators at the University of Texas Southwestern Medical Center (Dallas, USA) genetically engineered two distinct lines of mice, one that overexpressed miR-21 and one that did not express this microRNA at all.

They reported in the September 14, 2010, issue of the journal Cancer Cell that overexpression of miR-21 enhanced tumorigenesis, and that genetic deletion of miR-21 partially protected against tumor formation. More...
At 18 weeks of age, mice with overexpressed miR-21 had significantly more tumors than NSCLC animals with normal levels of miR-21. On the other hand, overexpression of miR-21 by itself did not induce cancer formation in otherwise healthy animals.

The investigators determined that at the molecular level miR-21 promoted tumorigenesis by inhibiting tumor suppressors of the Ras/MEK/ERK pathway, which in turn inhibited apoptosis and allowed the cancer cells to grow. Cancer cells growing in mice with no miR-21 expression were more susceptible to certain kinds of chemotherapy, suggesting that inhibiting miR-21 in lung-cancer patients could be of therapeutic value.

"Methods currently exist to pharmacologically manipulate molecules like miR-21,” said senior author Dr. Eric Olson, professor of molecular biology at the University of Texas Southwestern Medical Center. "More research will be needed before we know whether this is applicable to humans, but it's possible that a drug designed to inhibit miR-21 could help keep cancer at bay.”

Related Links:
University of Texas Southwestern Medical Center




New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Multi-Chamber Washer-Disinfector
WD 390
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.